Drugs / Providone-Iodine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT05747430 Comparator | Feb 2023 → Mar 2025 | retinal disorder | iRenix Medical, Inc. | Completed | Met primary |
| Phase 3 | NCT05750589 Comparator | Sep 2026 → Jan 2027 expected | retinal disorder | iRenix Medical, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Providone-Iodine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05747430 ↗ |